A Phase 2 Study of Eribulin in Patients with Metastatic Angiosarcoma and Epithelioid Hemangioendothelioma.

Cote GM, Aberoumand M, Choy E, Sebastian L, Mazzola E, Grimison P, Merriam P, Ballinger M, Thavaneswaran S, Lin F, Grady JP, Millward M, Brown MP, Harrup R, Espinoza D, Demetri G, Littlefield BA, Simes RJ, George S, Thomas D

Open source

DOI: 10.1158/1078-0432.ccr-25-3362
Published: 2026 Jun 1
Container: Clinical cancer research : an official journal of the American Association for Cancer Research
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1158/1078-0432.ccr-25-3362,
  title = {A Phase 2 Study of Eribulin in Patients with Metastatic Angiosarcoma and Epithelioid Hemangioendothelioma.},
  author = {Cote GM and Aberoumand M and Choy E and Sebastian L and Mazzola E and Grimison P and Merriam P and Ballinger M and Thavaneswaran S and Lin F and Grady JP and Millward M and Brown MP and Harrup R and Espinoza D and Demetri G and Littlefield BA and Simes RJ and George S and Thomas D},
  year = {2026},
  journal = {Clinical cancer research : an official journal of the American Association for Cancer Research},
  doi = {10.1158/1078-0432.ccr-25-3362},
  url = {https://doi.org/10.1158/1078-0432.ccr-25-3362}
}

RIS

TY  - JOUR
TI  - A Phase 2 Study of Eribulin in Patients with Metastatic Angiosarcoma and Epithelioid Hemangioendothelioma.
AU  - Cote GM
AU  - Aberoumand M
AU  - Choy E
AU  - Sebastian L
AU  - Mazzola E
AU  - Grimison P
AU  - Merriam P
AU  - Ballinger M
AU  - Thavaneswaran S
AU  - Lin F
AU  - Grady JP
AU  - Millward M
AU  - Brown MP
AU  - Harrup R
AU  - Espinoza D
AU  - Demetri G
AU  - Littlefield BA
AU  - Simes RJ
AU  - George S
AU  - Thomas D
PY  - 2026
JO  - Clinical cancer research : an official journal of the American Association for Cancer Research
DO  - 10.1158/1078-0432.ccr-25-3362
UR  - https://doi.org/10.1158/1078-0432.ccr-25-3362
ER  -

APA

GM, C., M, A., E, C., L, S., E, M., P, G., P, M., M, B., S, T., F, L., JP, G., M, M., MP, B., R, H., D, E., G, D., BA, L., RJ, S., S, G., & D, T. (2026). A Phase 2 Study of Eribulin in Patients with Metastatic Angiosarcoma and Epithelioid Hemangioendothelioma.. Clinical cancer research : an official journal of the American Association for Cancer Research. https://doi.org/10.1158/1078-0432.ccr-25-3362

Source records

pubmed · retrieved 2026-09-27T01:38:43.957Z